Seattle Genetics (SGEN), Takeda's Millennium Announce Deal with Ventana on Companion Diagnostic for ADCETRIS

Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have formed a collaboration with Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group. Under the collaboration agreement, Ventana will seek to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with ADCETRIS based on CD30 expression levels in their tissue specimens. As part of the ongoing clinical development of ADCETRIS, Millennium and Seattle Genetics are planning two phase III studies that will use the companion diagnostic, one in CD30-positive cutaneous T-cell lymphoma (CTCL) and the other in CD30-positive mature T-cell lymphomas (MTCL).

ADCETRIS was approved by the U.S. Food and Drug Administration in August 2011 for relapsed Hodgkin lymphoma (HL) and systemic anaplastic large call lymphoma (sALCL). A molecular companion diagnostic is not required for the current FDA-approved indications for ADCETRIS.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Kimbell Royalty closes $221.2M mineral rights acquisition
• Nu Skin EVP of global sales takes medical leave